Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban after intravenous reteplase for acute ischemic stroke
ChiCTR2600126685Phase 4Not yet recruiting
- Sponsor
- Pingshan District People's Hospital of Shenzhen
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirofiban in ischemic stroke, sponsored by Pingshan District People's Hospital of Shenzhen. Primary endpoint: Incidence of symptomatic intracranial hemorrhage within 48 hours. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600126685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126685.